enclomiphene
Enclomifene (INNTooltip International Nonproprietary Name), or enclomiphene (USANTooltip United States Adopted Name), a nonsteroidal selective estrogen receptor modulator of the triphenylethylene group, acts by antagonizing the estrogen receptor (ER) in the pituitary gland, which reduces negative feedback by estrogen on the hypothalamic-pituitary-gonadal axis, thereby increasing gonadotropin secretion and hence gonadal production of testosterone. It is one of the two stereoisomers of clomifene, which itself is a mixture of 38% zuclomifene and 62% enclomifene. Enclomifene is the (E)-stereoisomer of clomifene, while zuclomifene is the (Z)-stereoisomer. Whereas zuclomifene is more estrogenic, enclomifene is more antiestrogenic. In accordance, unlike enclomifene, zuclomifene is antigonadotropic due to activation of the ER and reduces testosterone levels in men. As such, isomerically pure enclomifene is more favorable than clomifene as a progonadotropin for the treatment of male hypogonadism. — Wikipedia
Clinical trial activity
24 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2006 (NCT00962637)
Timeline
Indications
Mechanism of action
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Chemistry & pharmacology
SMILES
CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O- Mol. weight
- 598.09 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnclomifene ↗
- ChEMBLCHEMBL1200667 ↗
Also known as
- enclomiphene citrate
- enclomiphene citrate
- enclomiphene citrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02651688 | Phase 2 | Jan 1, 2016 | Repros Therapeutics |
| NCT02160704 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2014 | Baylor University |
| NCT02274181 | Phase 1 | Dec 1, 2014 | Celerion, Repros Therapeutics |
| NCT02169804 | Phase 1 | Aug 1, 2014 | Repros Therapeutics |
| NCT02146391 | Phase 1 | Jun 1, 2014 | Repros Therapeutics |
| NCT01991327 | Phase 1 | May 1, 2014 | Repros Therapeutics |
| NCT02117830 | Phase 1 | Apr 1, 2014 | Repros Therapeutics |
| NCT01993225 | Phase 3 | Jan 1, 2014 | Repros Therapeutics |
| NCT01993212 | Phase 3 | Jan 1, 2014 | Repros Therapeutics |
| NCT01984398 | Phase 1 | Dec 1, 2013 | Repros Therapeutics |
| NCT01959685 | Phase 1 | Oct 1, 2013 | Repros Therapeutics |
| NCT01923870 | Phase 1 | Aug 1, 2013 | Repros Therapeutics |
| NCT01923857 | Phase 1 | Aug 1, 2013 | Repros Therapeutics |
| NCT01739582 | Phase 3 | Nov 1, 2012 | Repros Therapeutics |
| NCT01739595 | Phase 3 | Nov 1, 2012 | Repros Therapeutics |
| NCT01619683 | Phase 3 | Sep 1, 2012 | Repros Therapeutics |
| NCT01532414 | Phase 3 | Aug 1, 2012 | Repros Therapeutics |
| NCT01534208 | Phase 3 | May 1, 2012 | Repros Therapeutics |
| NCT01386567 | Phase 2 | Jul 1, 2011 | Repros Therapeutics |
| NCT01386606 | Phase 2 | Jun 1, 2011 | PRACS, Repros Therapeutics |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Repros Therapeutics | For profit | 23 | 23 | 3 | 2006 |
| Baylor University | Academic/Hospital | 3 | 1 | 2 | 2010 |
| Celerion | For profit | 1 | 0 | 1 | 2014 |
| PRACS | For profit | 1 | 0 | 1 | 2011 |